Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors

Cunningham, Kaitlynne N.; Rosmarin, David

doi:10.1007/s40257-022-00752-6

Cited by 25 publications

(17 citation statements)

References 278 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of participants included in our study had a history of prior therapy, including topical corticosteroids, calcineurin inhibitors, phototherapy and photochemotherapy, indicating that they were not rst-episode patients. Indeed, the effectiveness of ruxolitinib speci cally for rst-episode vitiligo patients and the potential bene ts of combining it with other treatments require further investigation [26,27] . Conducting future trials based on these hypotheses would provide valuable insights into the comparative e cacy of ruxolitinib in different patient populations and the potential synergistic effects of combination therapies that will contribute to advancing our understanding of the optimal treatment strategies for vitiligo.…”

Section: Discussionmentioning

confidence: 99%

Short-Term (24 Weeks) Treatment Efficacy and Safety of Ruxolitinib Cream in Participants with Vitiligo: A Systematic Review and Meta-Analysis

Yuan,

Zheng,

et al. 2024

Preprint

View full text Add to dashboard Cite

Importance Vitiligo is a chronic skin disorder causing depigmentation. There is lack of evidence-based medical evidence regarding ruxolitinib efficacy and safety for Vitiligo. Objective To assess the efficacy and safety of ruxolitinib cream in treatment vitiligo. Methods The databases of PubMed, Embase, and Cochrane Library were searched. The literature screening was independently conducted by two reviewers. Data extraction and synthesis For continuous variables, weighted mean difference (WMD) along with a 95% confidence interval (CI) was performed. For dichotomous outcomes, we calculated the odds ratios (ORs) or risk ratios (RRs), and their corresponding 95% CIs. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). Main outcomes and measures Symptoms, quality of life, and safety were evaluated using various measures, including the Facial Vitiligo Area Scoring Index (F-VASI), Total Vitiligo Area Scoring Index (T-VASI), Facial Body Surface Area (F-BAS), Total Body Surface Area (T-BAS) and Treatment-emergent Adverse Events (TEAEs). Results Three trials, involving a total of 830 participants from nine countries were included (female: 388, 46.7%, male: 442, 53.3%). The meta-analysis demonstrated a significant increase in the likelihood of participants achieving F-VASI75 (OR, 4.34 [95% CI, 2.67-7.06]; high), F-VASI50 (OR, 4.71 [95% CI, 3.24-6.84]; high), T-VASI75 (OR, 2.78 [95% CI, 1.10-7.00]; moderate), and T-VASI50 (OR, 4.47 [95% CI, 2.52-7.92]; high) when compared ruxolitinib to vehicle. Ruxolitinib were associated with more lowered percentage change of F-VASI scores (MD, –32.79 [95% CI, −36.37 to −29.21]; moderate), and T-VASI scores (MD, –20.22 [95% CI, −23.11 to −17.33]; moderate) from baseline compared to vehicle. There may not be a significant difference in the occurrence of TEAEs between ruxolitinib and vehicle (RR, 1.46 [95% CI, 0.85-2.49]; high). Conclusions The findings suggest that ruxolitinib cream holds promise as a treatment option for vitiligo. Further long-term studies are needed to assess its sustained efficacy and safety profile.

show abstract

Section: Discussionmentioning

confidence: 99%

Short-Term (24 Weeks) Treatment Efficacy and Safety of Ruxolitinib Cream in Participants with Vitiligo: A Systematic Review and Meta-Analysis

Yuan,

Zheng,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Multiple breakthroughs have been made in the research on the pathophysiology and treatment modalities for vitiligo. 23 Phototherapy still is an indispensable component of vitiligo treatment regimens. Novel targeted phototherapy devices, such as the 308-nm LED, are safe and effective for treating vitiligo, which helps reduce the time and costs associated with the therapy and improve patient compliance.…”

Section: Discussionmentioning

confidence: 99%

“…Multiple breakthroughs have been made in the research on the pathophysiology and treatment modalities for vitiligo 23 . Phototherapy still is an indispensable component of vitiligo treatment regimens.…”

Section: Discussionmentioning

confidence: 99%

Comparing the efficacy of 308‐nm light‐emitting diode and 308‐nm excimer lamp for treating vitiligo: A randomized controlled trial

Hu,

Liu,

et al. 2024

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

BackgroundIn previous studies, the 308‐nm light‐emitting diode (LED) has been proven safe and effective for treating vitiligo. However, direct comparisons between the 308‐nm LED and 308‐nm excimer lamp (308‐nm MEL) for the treatment of vitiligo are lacking.ObjectiveTo compare the efficacy of the 308‐nm LED and 308‐nm MEL for treating nonsegmental stable vitiligo.Patients and MethodsThis randomized controlled trial was conducted between January 2018 and August 2023. Enrolled patients were randomly assigned to either the 308‐nm LED or the 308‐nm MEL groups, both receiving 16 treatment sessions. Adverse events that occurred during the treatment were documented.ResultsIn total, 269 stable vitiligo patches from 174 patients completed the study. A total of 131 lesions were included in the 308‐nm LED group, and 138 lesions were included in the 308‐nm MEL group. After 16 treatment sessions, 38.17% of the vitiligo patches in the 308‐nm LED group achieved repigmentation of at least 50% versus 38.41% in the 308‐nm MEL group. The two devices exhibited similar results in terms of efficacy for a repigmentation of at least 50% (p = .968). The incidence of adverse effects with the two phototherapy devices was comparable (p = .522).ConclusionsTreatment of vitiligo with the 308‐nm LED had a similar efficacy rate to the 308‐nm MEL, and the incidence of adverse effects was comparable between the two devices.

show abstract

“…The therapeutic modalities in vitiligo involve: topical corticosteroids, immunomodulators, PT, oral corticosteroids, Januskinase inhibitors, surgical interference, lasers, and depigmentation therapies. In spite of the novel advances in vitiligo treatment, outcomes remain mostly not satisfied and several cases demonstrate no or mild response [10] .…”

Section: Discussionmentioning

confidence: 99%

Comparative Study between the Efficacy of Trichloroacetic Acid 30% versus Intradermal 5 Fluorouracil Injection in Treatment of Vitiligo with or without Narrow Band Ultraviolet B Phototherapy

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Vitiligo is a challenging disease, which significantly impaired quality of life (QoL). In recent years, there are numerous therapeutic modalities available that aim to stop progression with a subsequent induction of skin repigmentation. Combination among different modalities could improve the response, reduces the adverse events, and reduces the course required to achieve re-pigmentation in vitiligo. Objective: To compare the efficacy of trichloroacetic acid (TCA) chemical peel (30% concentration) versus intradermal injection of 5 Fluorouracil Injection (5-FU) both with and without Narrow Band Ultraviolet B (NB-UVB) Phototherapy (PT) in management of stable non-segmental vitiligo (NSV). Patients and Methods: This comparative prospective interventional study comprised 60 patients with stable NSV. Patients were divided into two equal groups: Group I and group II. Lesion 1 in both groups was treated with only TCA 30%, while, lesion 2 was treated with only intradermal injection of 5-FU. In group II, each lesion was followed by the application of NBUVB sessions twice/week. Results: Based on the Physician's Global Assessment (PGA) score, the present study demonstrated a highly statistically significant increase in the percentage of improvement among group II compared to group I. According to the PGA score, our study demonstrated a statistically significant increase in the percentage of improvement among the subgroup 5-FU II+ NBUVB compared to 5-FU I. Conclusion: It could be concluded that the combination therapies of each of TCA or 5-FU with NBUVB ranked higher than monotherapy with either TCA or 5-FU in inducing successful re-pigmentation in stable NSV patients.

show abstract

Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors

Cited by 25 publications

References 278 publications

Short-Term (24 Weeks) Treatment Efficacy and Safety of Ruxolitinib Cream in Participants with Vitiligo: A Systematic Review and Meta-Analysis

Short-Term (24 Weeks) Treatment Efficacy and Safety of Ruxolitinib Cream in Participants with Vitiligo: A Systematic Review and Meta-Analysis

Comparing the efficacy of 308‐nm light‐emitting diode and 308‐nm excimer lamp for treating vitiligo: A randomized controlled trial

Comparative Study between the Efficacy of Trichloroacetic Acid 30% versus Intradermal 5 Fluorouracil Injection in Treatment of Vitiligo with or without Narrow Band Ultraviolet B Phototherapy

Contact Info

Product

Resources

About